Syndax Pharmaceuticals

#Acute Myeloid Leukaemia #Cancer research #Leukaemia #Oncology #Syndax Pharmaceuticals

Leading the charge in cancer care

DDW Editor Reece Armstrong speaks to Michael Metzger, CEO of Syndax, about its work on developing therapeutics for challenging cancer targets.    RA: What are the unmet needs in relapsed or refractory acute leukaemia. How great is this unmet need in paediatric patients?   MM: Syndax is initially focused on two… Read More

#Exclusive Content

Stem cells
#FDA #Graft vs Host Disease #Incyte #Syndax Pharmaceuticals

FDA approves Niktimvo for chronic graft-versus-host disease

The US Food and Drug Administration (FDA) has approved axatilimab-csfr (Niktimvo), a colony stimulating factor-1 receptor-blocking antibody, for the treatment of chronic graft-versus-host disease (cGVHD). It is approved for use after the failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least… Read More

#News #Regulatory